|
1
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ramalingam SS, Vansteenkiste J, Planchard
D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y,
Chewaskulyong B, et al: Overall survival with Osimertinib in
untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 382:41–50.
2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Grangeon M, Tomasini P, Chaleat S, Jeanson
A, Souquet-Bressand M, Khobta N, Bermudez J, Trigui Y, Greillier L,
Blanchon M, et al: Association between immune-related adverse
events and efficacy of immune checkpoint inhibitors in
non-small-cell lung cancer. Clin Lung Cancer. 20:201–207.
2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ricciuti B, Genova C, De Giglio A,
Bassanelli M, Dal Bello MG, Metro G, Brambilla M, Baglivo S, Grossi
F and Chiari R: Impact of immune-related adverse events on survival
in patients with advanced non-small cell lung cancer treated with
nivolumab: Long-term outcomes from a multi-institutional analysis.
J Cancer Res Clin Oncol. 145:479–485. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Wang DY, Salem JE, Cohen JV, Chandra S,
Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al: Fatal
toxic effects associated with immune checkpoint inhibitors: A
systematic review and meta-analysis. JAMA Oncol. 4:1721–1728.
2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Emami B, Lyman J, Brown A, Coia L, Goitein
M, Munzenrider JE, Shank B, Solin LJ and Wesson M: Tolerance of
normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol
Phys. 21:109–122. 1991.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Bang A, Wilhite TJ, Pike LRG, Cagney DN,
Aizer AA, Taylor A, Spektor A, Krishnan M, Ott PA, Balboni TA, et
al: Multicenter evaluation of the tolerability of combined
treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and
palliative radiation therapy. Int J Radiat Oncol Biol Phys.
98:344–351. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Qin R, Olson A, Singh B, Thomas S, Wolf S,
Bhavsar NA, Hanks BA, Salama JK and Salama AK: Safety and efficacy
of radiation therapy in advanced melanoma patients treated with
ipilimumab. Int J Radiat Oncol Biol Phys. 96:72–77. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Barker CA, Postow MA, Khan SA, Beal K,
Parhar PK, Yamada Y, Lee NY and Wolchok JD: Concurrent radiotherapy
and ipilimumab immunotherapy for patients with melanoma. Cancer
Immunol Res. 1:92–98. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Antonia SJ, Villegas A, Daniel D, Vicente
D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, et
al: Overall survival with durvalumab after chemoradiotherapy in
stage III NSCLC. N Engl J Med. 379:2342–2350. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Patel RR, He K, Barsoumian HB, Chang JY,
Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, et al:
High-dose irradiation in combination with non-ablative low-dose
radiation to treat metastatic disease after progression on
immunotherapy: Results of a phase II trial. Radiother Oncol.
162:60–67. 2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
National Cancer Institute: Common
terminology criteria for adverse events (CTCAE) v.5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
Accessed July 22, 2021.
|
|
13
|
Sprave T, Verma V, Förster R, Schlampp I,
Bruckner T, Bostel T, Welte SE, Tonndorf-Martini E, El Shafie R,
Nicolay NH, et al: Radiation-induced acute toxicities after
image-guided intensity-modulated radiotherapy versus
three-dimensional conformal radiotherapy for patients with spinal
metastases (IRON-1 trial): First results of a randomized controlled
trial. Strahlenther Onkol. 194:911–920. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bassanelli M, Ricciuti B, Giannarelli D,
Cecere FL, Roberto M, Giacinti S, Barucca V, Santarelli M, Ruggeri
EM, Marchetti P, et al: Systemic effect of radiotherapy before or
after nivolumab in lung cancer: An observational, retrospective,
multicenter study. Tumors 3008916211004733, 2021 (Epub ahead of
print).
|
|
15
|
Schaue D, Ratikan JA, Iwamoto KS and
McBride WH: Maximizing tumor immunity with fractionated radiation.
Int J Radiat Oncol Biol Phys. 83:1306–1310. 2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Dewan MZ, Galloway AE, Kawashima N,
Dewyngaert JK, Babb JS, Formenti SC and Demaria S: Fractionated but
not single-dose radiotherapy induces an immune-mediated abscopal
effect when combined with anti-CTLA-4 antibody. Clin Cancer Res.
15:5379–5388. 2009.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Dunlop RJ and Campbell CW: Cytokines and
advanced cancer. J Pain Symptom Manag. 20:214–232. 2000.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Uchida A, Mizutani Y, Nagamuta M and
Ikenaga M: Effects of X-ray irradiation on natural killer (NK) cell
system. II. Increased sensitivity to natural killer cytotoxic
factor (NKCF). Immunopharmacol Immunotoxicol. 11:521–534.
1989.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Agrawal A, Chandra D and Kale RK:
Radiation induced oxidative stress: II studies in liver as a
distant organ of tumor bearing mice. Mol Cell Biochem. 224:9–17.
2001.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Postow MA, Sidlow R and Hellmann MD:
Immune-related adverse events associated with immune checkpoint
blockade. N Engl J Med. 378:158–168. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Azria D, Magné N, Zouhair A, Castadot P,
Culine S, Ychou M, Stupp R, Van Houtte P, Dubois JB and Ozsahin M:
Radiation recall: A well recognized but neglected phenomenon.
Cancer Treat Rev. 31:555–570. 2005.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Marthey L, Mateus C, Mussini C, Nachury M,
Nancey S, Grange F, Zallot C, Peyrin-Biroulet L, Rahier JF,
Bourdier de Beauregard M, et al: Cancer immunotherapy with
anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel
disease. J Crohns Colitis. 10:395–401. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Soularue E, Lepage P, Colombel JF, Coutzac
C, Faleck D, Marthey L, Collins M, Chaput N, Robert C and Carbonnel
F: Enterocolitis due to immune checkpoint inhibitors: A systematic
review. Gut. 67:2056–2067. 2018.PubMed/NCBI View Article : Google Scholar
|
